Earnings per Share (EPS) is expected to be $1.58, indicating a 49.1% increase year-over-year.
Projected revenue is at $1.15 billion, showing a 13.5% growth from the previous year.
Incyte’s stock has surged by 27.1% over the past year, outperforming the industry’s 9.9% decline.

Incyte Corporation (NASDAQ:INCY), a leading biopharmaceutical company, is renowned for its innovative therapies, including Jakafi and Opzelura. These drugs play a crucial role in treating conditions such as polycythemia vera and myelofibrosis. Incyte stands in competition with pharmaceutical giants like Bristol-Myers Squibb and Novartis, focusing on similar therapeutic areas.
On February 11, 2025, Incyte is poised to release its quarterly earnings. Analysts are optimistic, expecting an EPS of $1.58, reflecting a 49.1% increase from the previous year. Revenue is also anticipated to reach $1.15 billion, marking a 13.5% year-over-year growth.
The upward revision of the EPS estimate by 3.2% over the past 30 days suggests a positive outlook from analysts. Such revisions can significantly impact investor sentiment and short-term stock price movements. Incyte’s stock has already surged by 27.1% over the past year, contrasting with a 9.9% decline in the industry, highlighting its strong market performance.
Incyte’s financial metrics reveal a high valuation, with a price-to-earnings (P/E) ratio of 439.62 and a price-to-sales ratio of 3.50. The enterprise value to sales ratio is 3.19, while the enterprise value to operating cash flow ratio is notably high at 127.77. These figures suggest that investors have high expectations for the company’s future growth.
Despite the high valuation, Incyte maintains a strong financial position with a minimal debt-to-equity ratio of 0.012 and a current ratio of 1.87. This indicates the company’s low leverage and strong ability to cover short-term liabilities, providing a stable foundation for its continued growth and development in the biopharmaceutical industry.